多激酶抑制剂治疗难治性甲状腺癌的疗效与安全性:系统评价与网状Meta分析
该系统评价与网状Meta分析检索MEDLINE、EMBASE和Cochrane数据库至2023年12月,纳入比较多激酶抑制剂(MKI)与安慰剂或其他MKI的随机对照试验,采用贝叶斯网状Meta分析。结果显示,卡博替尼60 mg/日(CAB60)在放射性碘难治性分化型甲状腺癌(RAIR-DTC)中与最长的无进展生存期(PFS)相关,CAB60、LEN24、阿帕替尼和索拉非尼在RAIR-DTC中总生存期(OS)改善显著;在晚期甲状腺髓样癌(aMTC)中CAB140、CAB60或安罗替尼改善PFS,但OS无统计学差异;高剂量MKI较低剂量增加不良事件发生率。
要点
- 在RAIR-DTC患者中,CAB60与最长的PFS相关,其次为LEN18或LEN24及阿帕替尼。
- 在aMTC患者中,CAB140、CAB60或安罗替尼改善PFS。
- 高剂量MKI(CAB、LEN、凡德他尼)较低剂量增加不良事件发生率。
核心结论
- CAB60、LEN和阿帕替尼是RAIR-DTC患者中有前景的局部MKI,主要结局具有统计学显著性。
- CAB和安罗替尼在aMTC患者中有效延长PFS。
研究设计与样本
- 系统评价与网状Meta分析,检索MEDLINE(通过PubMed)、EMBASE和Cochrane数据库,从建库至2023年12月。
- 纳入比较MKI与其他MKI或安慰剂的随机对照试验。
- 采用Cochrane偏倚风险2工具分析偏倚风险,进行贝叶斯网状Meta分析。
- 治疗按MKI类型分组为共同节点。
主要发现
- 在RAIR-DTC患者中,CAB60与最长的PFS相关,其次为LEN18或LEN24,以及阿帕替尼。
- 在aMTC患者中,接受CAB140、CAB60或安罗替尼治疗者PFS也改善。
- 在RAIR-DTC患者中,CAB60、LEN24、安罗替尼和索拉非尼的OS改善显著更优。
- 在aMTC患者中,OS缺乏统计学差异。
- 与低剂量MKI相比,高剂量MKI如CAB、LEN和凡德他尼增加不良事件发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Multikinase inhibitors (MKIs) improve the treatment of refractory thyroid cancer, including radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) and advanced medullary thyroid carcinoma (aMTC). OBJECTIVE: This study aims to compare the efficacy of MKIs in improving survival outcomes and safety. DATA SOURCES: Comprehensive database searches of MEDLINE via PubMed, EMBASE, and Cochrane were performed from inception to December 2023. STUDY SELECTION: Three independent authors selected these studies. Randomized controlled trials that compared the use of a MKI to other MKIs or placebo were included. DATA EXTRACTION AND SYNTHESIS: This review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Risk of bias was analyzed using the Cochrane risk of bias 2 tool. Bayesian network meta-analysis was performed. Treatments were grouped into common nodes based on the type of MKI. MAIN OUTCOMES AND MEASURES: Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate, disease control rate, clinical benefit rate, and adverse events. RESULTS: Cabozantinib 60 mg/day (CAB60) was associated with the highest prolonged PFS in RAIR-DTC patients, followed by lentivatinib 18 or 24 mg/day (LEN18 or LEN24), and apatinib. PFS was also improved in aMTC patients who received CAB 140 mg/day (CAB140), CAB60, or anlotinib. A significantly greater improvement on the performance of OS was seen in CAB60, LEN24, anlotinib, and sorafenib in RAIR-DTC patients, but in aMTC patients there were lack of statistical differences. Compared with the low-dose MKIs, high-dose MKIs such as CAB, LEN, and vandetanib increased the incidence of adverse events. CONCLUSION: CAB60, LEN, and apatinib are promising topical MKIs with statistically significant primary outcomes in RAIR-DTC patients, while CAB and anlotinib are effective in prolonging PFS in aMTC patients.
引用
- Jing R, Wu N, Wu Y, et al. Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab. 2024. PMID: 38970485. doi:10.1210/clinem/dgae454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。